• Sanofi's Dupixent gets Europe eczema nod pharmatimes
    September 29, 2017
    The European Commission has given marketing authorisation for Dupixent (dupilumab), the first targeted biologic in Europe to treat the most common form of eczema.
PharmaSources Customer Service